2016•Value in HealthOpen access

Cost-Utility Analysis of First-Line Gefitinib, Erlotinib and Afatinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations

MS Holleman, Remziye Zaim, CA Uyl‐de Groot

Open full text 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Erlotinib, Afatinib, Gefitinib, Medicine, Epidermal growth factor receptor, Lung cancer, Erlotinib Hydrochloride, Oncology

Back to paper search Browse research topics Original source

Cost-Utility Analysis of First-Line Gefitinib, Erlotinib and Afatinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations — Research Paper | ScholarLens